Award-winning device designed for patient ease of use, reliability and convenience
EMD Serono, Inc. announced today the availability of easypod®, the first of its kind automated device in the growth hormone therapeutic area. easypod® was developed for the administration of Saizen® [somatropin (rDNA origin) for injection], the company's treatment for growth hormone deficiency. A 2007 Gold Medal recipient of the Medical Design Excellence Awards®, easypod® was designed in conjunction with patients, caregivers and healthcare professionals to answer the need for a device that provided simple everyday use while monitoring patient adherence. On October 31, 2007, easypod® received approval from the US Food and Drug Administration (FDA) and is now available to patients through their healthcare providers.